"Centering the body and its sonorous movements provides an opportunity to examine multiple cellistic corporealities as the cellist-body interacts with instruments, objects, technologies, virtual performers, and machinic partners." academicworks.cuny.edu/gc_etds/5425/
Sonorous Movement: Cellistic Corporealities in Works by Helmut Lachenmann, Simon Steen-Andersen, and Johan Svensson
In Sonorous Movement: Cellistic Corporealities in Works by Lachenmann, Steen-Andersen, and Svensson, I analyze three compositions that foreground the cellist-body, its physical gestures, and instrumen...
academicworks.cuny.edu
December 27, 2025 at 11:19 PM
"Centering the body and its sonorous movements provides an opportunity to examine multiple cellistic corporealities as the cellist-body interacts with instruments, objects, technologies, virtual performers, and machinic partners." academicworks.cuny.edu/gc_etds/5425/
"BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell"
bioinformant.com/brightpath-b...
Companies to advance novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for trials.
bioinformant.com/brightpath-b...
Companies to advance novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for trials.
BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell | BioInformant
Tokyo, Japan and Mont-Saint-Guibert, Belgium, – December 13th, 2024 – BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell thera...
bioinformant.com
January 12, 2025 at 7:46 PM
"BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell"
bioinformant.com/brightpath-b...
Companies to advance novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for trials.
bioinformant.com/brightpath-b...
Companies to advance novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for trials.
#Cellistic #iPSCbasedplatforms #immunooncologytherapies #celltherapydevelopment #GMPmanufacturing #iPSCderivedcelltherapies #immunooncology #regenerativemedicine #EchoT #EchoCardio #EchoEndothelial #allogeneiccelltherapy #EchoNKsystem #celltherapy #autologousTcelltherapies #Tregs
zurl.co/EF2mP
zurl.co/EF2mP
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies - PharmaTimes
New manufacturing technologies aim to accelerate next-generation cell therapy development
pharmatimes.com
January 22, 2026 at 11:00 AM
Feed: "PharmaTimes"
By: John Pinching on Tuesday, January 13, 2026
By: John Pinching on Tuesday, January 13, 2026
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
New manufacturing technologies aim to accelerate next-generation cell therapy development
pharmatimes.com
January 14, 2026 at 12:07 AM
Feed: "PharmaTimes"
By: John Pinching on Tuesday, January 13, 2026
By: John Pinching on Tuesday, January 13, 2026
Cellistic Announces Successful CRISPR intellectual property Asset Purchase -… https://news.google.com/rss/articles/CBMiYGh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9jZWxsaXN0aWMtYW5ub3VuY2VzLXN1Y2Nlc3NmdWwtY3Jpc3ByLWludGVsbGVjdHVhbC0xMjI0MDA2NTUuaHRtbNIBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
April 4, 2024 at 12:37 PM
Cellistic Announces Successful CRISPR intellectual property Asset Purchase -… https://news.google.com/rss/articles/CBMiYGh0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9jZWxsaXN0aWMtYW5ub3VuY2VzLXN1Y2Nlc3NmdWwtY3Jpc3ByLWludGVsbGVjdHVhbC0xMjI0MDA2NTUuaHRtbNIBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
Cellistic Announces Successful… https://news.google.com/rss/articles/CBMigwFodHRwczovL3d3dy5idXNpbmVzc3dpcmUuY29tL25ld3MvaG9tZS8yMDI0MDQwNDY1NzQ4Ny9lbi9DZWxsaXN0aWMtQW5ub3VuY2VzLVN1Y2Nlc3NmdWwtQ1JJU1BSLWludGVsbGVjdHVhbC1wcm9wZXJ0eS1Bc3NldC1QdXJjaGFzZdIBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
April 4, 2024 at 12:32 PM
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - bioinformant.com/cellistic-ne...
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies | BioInformant
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy m...
bioinformant.com
January 15, 2026 at 12:57 AM
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - bioinformant.com/cellistic-ne...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...
bioinformant.com
November 9, 2025 at 5:46 AM
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...
bioinformant.com
July 12, 2025 at 11:19 AM
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies - bioinformant.com/cellistic-la...
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies | BioInformant
Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of a...
bioinformant.com
April 10, 2025 at 10:22 PM
Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies - bioinformant.com/cellistic-la...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based - An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD | BioInformant
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogen...
bioinformant.com
March 10, 2025 at 3:14 PM
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD - bioinformant.com/cellistic-st...
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked #iPSC Cell Lines facilitating cost-effective cell therapy development - bioinformant.com/cellistic-la...
March 3, 2025 at 5:51 PM
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked #iPSC Cell Lines facilitating cost-effective cell therapy development - bioinformant.com/cellistic-la...